Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Ton Rabelink"'
Autor:
Cees van Kooten, Y K Onno Teng, Willem Jan Bos, Obbo W Bredewold, Argho Ray, Jacqueline T Jonker, Hilde H F Remmelts, Ebru Dirikgil, Jolijn R van Leeuwen, Darius Soonawala, Bastiaan van Dam, Joris Rotmans, Ton Rabelink, Laura S van Dam
Publikováno v:
BMJ Open, Vol 12, Iss 9 (2022)
Introduction Both rituximab (RTX) and cyclophosphamide (CYC) are effectively used in combination with steroids as remission induction therapy for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Several studies ha
Externí odkaz:
https://doaj.org/article/93e10e71ff174e9784e45f43637e181b
Autor:
Hans-Joachim Anders, Brad Rovin, David Jayne, Paul Brunetta, Rosanna Coppo, Anne Davidson, Satish Kumar Devarapu, Dick de Zeeuw, Jeremy Duffield, Dirk Eulberg, Alberto Fierro, Jürgen Floege, Steffen Frese, Loïc Guillevin, Stephen Holdsworth, Jeremy Hughes, Ralph Kettritz, Malte Kluger, Christian Krebs, Larissa Lapteva, Adeera Levin, Jinhua Li, Liz Lightstone, Matthias Mack, Ladan Mansouri, Stephen McAdoo, Eoin McKinney, Ulf Panzer, Samir Parikh, Charles Pusey, Chaim Putterman, Ton Rabelink, Andreas Radbruch, Andrew Rees, Mary Reilly, Marlies Reinders, Giuseppe Remuzzi, Piero Ruggenenti, Steven Sacks, Thomas J Schall, Catherine Meyer-Schwesinger, Kumar Sharma, Yusuke Suzuki, Nicola M. Tomas, Ming-Hui Zhao
Publikováno v:
Kidney International Reports, Vol 1, Iss 4, Pp 327-339 (2016)
To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the Inter
Externí odkaz:
https://doaj.org/article/31c0023f19ae480299b2c0347a697892
Autor:
Marina A Aleksinskaya, Ernst E H van Faassen, Jelly Nelissen, Ben J A Janssen, Jo G R De Mey, Roeland Hanemaaijer, Ton Rabelink, Anton Jan van Zonneveld
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e57761 (2013)
Nitric oxide (NO) has been implicated in matrix metallopeptidase 9 (MMP9)-dependent mobilization of hematopoietic stem and progenitor cells from bone marrow (BM). However, direct measurement of NO in the BM remained elusive due to its low in situ con
Externí odkaz:
https://doaj.org/article/f5783a14b1194100aa250447e93a484b
Autor:
Ebru Dirikgil, Jolijn R van Leeuwen, Laura S van Dam, Obbo W Bredewold, Argho Ray, Jacqueline T Jonker, Darius Soonawala, Hilde H F Remmelts, Bastiaan van Dam, Willem Jan Bos, Cees van Kooten, Joris Rotmans, Ton Rabelink, Y K Onno Teng
Publikováno v:
BMJ Open, 12(9). BMJ PUBLISHING GROUP
IntroductionBoth rituximab (RTX) and cyclophosphamide (CYC) are effectively used in combination with steroids as remission induction therapy for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Several studies hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba516f06da3bc51c3c9c50e85bdb92a0
https://hdl.handle.net/1887/3563164
https://hdl.handle.net/1887/3563164
Publikováno v:
Nephrology Dialysis Transplantation. 37
BACKGROUND AND AIMS Diabetic nephropathy (DN), chronic loss of kidney function due to diabetes mellitus, is a common complication in diabetes which currently lacks effective long-term treatment. Microalbuminuria is now the earliest marker for DN, the
Autor:
Eline J Arends, Mihaela Zlei, Christopher M Tipton, Zgjim Osmani, Fenna de Bie, Sylvia W A Kamerling, Ton Rabelink, Ignacio Sanz, Jacques J M Van Dongen, Cees van Kooten, Yeo K O Teng
Publikováno v:
Nephrology Dialysis Transplantation. 37
BACKGROUND AND AIMS Belimumab (BEL), a recombinant human monoclonal antibody directed against B-cell activating factor (BAFF), is the first approved biological agent for patients with systemic lupus erythematosus (SLE) and a high level of disease act
Autor:
Ton Rabelink, Y.K. Onno Teng
Publikováno v:
Clinical Journal of the American Society of Nephrology. :CJN.0069-01
Autor:
Berden, A. E., Beeres, S. L. M. A., Crobach, S., Schalij, M. J., Ton Rabelink, Teng, Y. K. O.
Publikováno v:
Clinical and Experimental Rheumatology, 34(3), S146-S146
ResearcherID
ResearcherID
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::05286c50f937fa0467ad94a073f545d4
https://hdl.handle.net/1887/113342
https://hdl.handle.net/1887/113342
Autor:
Zhang, H., Bruin, R. G., Sol, W. M. P. J., Veer, E. P., Den Berg, B. M., Ton Rabelink, Zonneveld, A. J., Gils, J. M.
Publikováno v:
ResearcherID
Atherosclerosis, 252, E157-E157
Atherosclerosis, 252, E157-E157
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::54ef8eae363001b692f6a0d4a0ab296a
https://hdl.handle.net/1887/113737
https://hdl.handle.net/1887/113737
Autor:
Ton Rabelink, Sadayoshi Ito, Paolo Pozzilli, Giuseppe Remuzzi, Jan Brož, Tatiana Kuznetsova, A.S. Ametov, Alexandre Persu, Renata Cífková, Vladimir Zadionchenko, Stefano Genovese, Irina Chazova, Piotr Ponikowski, JUAN ANTONIO DIVISÓN GARROTE, Larisa Yena, Krzysztof Narkiewicz, Luis M Ruilope
Publikováno v:
Vrije Universiteit Brussel
Europe PubMed Central
New England Journal of Medicine, 364(10), 907-917. MASSACHUSETTS MEDICAL SOCIETY
Europe PubMed Central
New England Journal of Medicine, 364(10), 907-917. MASSACHUSETTS MEDICAL SOCIETY
A b s t r ac t Background Microalbuminuria is an early predictor of diabetic nephropathy and premature cardiovascular disease. We investigated whether treatment with an angiotensin-receptor blocker (ARB) would delay or prevent the occurrence of micro